We partner with industry, charity, academic and clinical organisations, as well as NIHR infrastructure, providing the expertise and state-of the art, purpose-built facilities to deliver high-quality experimental medicine studies.
Partners benefit from our links with internationally-renowned clinicians and key opinion leaders, and access to extensive patient groups as well as healthy volunteers. We have a proven track record of delivering complex trials to time and target for over 20 years.
Over half of our active research portfolio is delivering commercial studies, from first-in-human to complex phase 3 clinical trials in a wide range of health specialties, including pharmaceuticals, immune therapies, advanced therapy medicinal products (ATMPs) and medical devices.
Together with our campus investigators, we have built many successful partnerships with commercial companies, from large multinational pharmaceutical companies such as AstraZeneca, GSK, Roche, Novartis, MSD and Incyte to smaller, pioneering biotech and medtech companies such as Agios Pharmaceuticals, CellCentric, Owlstone Medical and many more.